Publications by authors named "Valentina Boni"

28Publications

Increased vulnerability of clinical research units during the COVID-19 crisis and their protection.

Cancer 2020 09 2;126(17):3907-3911. Epub 2020 Jun 2.

START Madrid-HM Centro Integral Oncológico Clara Campal (CIOCC) Early Phase Program, HM Sanchinarro University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32980DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300769PMC
September 2020

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.

Am Soc Clin Oncol Educ Book 2020 Mar;40:1-17

START (South Texas Accelerated Research Therapeutics), San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_281107DOI Listing
March 2020

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.

Clin Cancer Res 2020 03 10;26(5):984-989. Epub 2019 Oct 10.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1457DOI Listing
March 2020

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Eur J Cancer 2018 11 1;104:1-8. Epub 2018 Oct 1.

Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.07.011DOI Listing
November 2018

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

Immunotherapy-based combinations: current status and perspectives.

Curr Opin Oncol 2017 Sep;29(5):382-394

aSTART Madrid-Centro Integral Oncológico Clara Campal, Sanchinarro University Hospital, Madrid, Spain bCentro Hospitalar Lisboa Norte EPE, Hospital de Santa Maria, Oncology Department, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000391DOI Listing
September 2017

The future of oncology therapeutics.

Expert Rev Anticancer Ther 2017 07 22;17(7):563-565. Epub 2017 May 22.

b START Madrid , Oncology Phase I Unit, Centro Integral Oncológico Clara Campal , Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1331131DOI Listing
July 2017

Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.

Invest New Drugs 2016 Apr 14;34(2):193-201. Epub 2016 Jan 14.

Research and Development Department, Spectrum Pharmaceuticals, 157 Technology Drive, Irvine, CA, 92618, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0321-8DOI Listing
April 2016

Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array.

World J Gastroenterol 2012 Feb;18(7):637-45

Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Avda Pio XII 55, 31008 Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v18.i7.637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281220PMC
February 2012

MiRNAs and LincRNAs: Could they be considered as biomarkers in colorectal cancer?

Int J Mol Sci 2012 16;13(1):840-65. Epub 2012 Jan 16.

Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona-Navarra 31008, Spain; E-Mails: (V.B.); (J.G.-F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms13010840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269724PMC
February 2015

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.

Eur J Cancer 2012 Aug 2;48(12):1774-80. Epub 2012 Feb 2.

Unit for the Research and Treatment of Gastrointestinal Malignancies, Department of Medical Oncology, University Clinic of Navarra, Pamplona, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.01.007DOI Listing
August 2012

MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.

Stem Cells 2011 Nov;29(11):1661-71

Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.741DOI Listing
November 2011